Your AI-Trained Oncology Knowledge Connection!
Opinion
Video
Author(s):
Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process.
Video content above is prompted by the following:
May 9th 2025 - Jun 14th 2025
May 8th 2025 - May 9th 2026
May 2nd 2025 - Jun 7th 2025
May 14th 2025 - May 15th 2026
May 13th 2025 - Jun 18th 2025
May 9th 2025 - Jun 14th 2025
May 8th 2025 - May 9th 2026
May 2nd 2025 - Jun 7th 2025
May 14th 2025 - May 15th 2026
May 13th 2025 - Jun 18th 2025
May 9th 2025 - Jun 14th 2025
May 8th 2025 - May 9th 2026
May 2nd 2025 - Jun 7th 2025
Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer
Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC
Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer
Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer
2 Commerce Drive
Cranbury, NJ 08512